No Surprises in Momenta's 4Q Results as Copaxone Launch Should Improve Near-Term Outlook
While we were largely unsurprised by Momenta's fourth-quarter 2017 performance, we plan to revisit our assumptions following the firm's recent approval and launch of its generic Copaxone 40 mg product in the U.S. with partner Novartis. Regardless, we do not anticipate significant changes to our fair value estimate at this time, and we are reiterating our no-moat rating.While Momenta's recent generic Copaxone 40 mg launch should help improve the company's financial picture, we expect intensifyin...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.